Activation of V2 vasopressin receptors induces recovery of motor function in patients with stroke, Parkinson's disease and parkinsonism of different nature

Svetlana G Belokoskova, Sergei G Tsikunov
2016 Reviews on Clinical Pharmacology and Drug Therapy  
In clinical trials have studied effectiveness of agonist of V2 vasopressin receptors, 1-dezamino-8-D-arginine-vasopressin (DDAVP) in correction of movement disorders in patients with stroke, Parkinson's disease and parkinsonism. Therapy received 15 patients with the stroke and 21 patients with the Parkinson's disease and parkinsonism. Positive effect of therapy was observed in 67% of cases of stroke and in 73% cases of parkinsonian syndrome. After therapy of DDAVP movement disorders were
more » ... sorders were regressed in patients with light hemiparesis after stroke. In patients with a tremor-rigid shape and akinetic-rigid form of the disease major movement disorders: tremor, rigidity, bradykinesia and hypokinesia were regressed. Except the disorders of movements affective and cognitive abnormalities were decreased. There was established that DDAVP effective in correction of disorders of voluntary and involuntary component of movements function in patients with the focal vascular and neurodegenerative diseases.
doi:10.17816/rcf14452-60 fatcat:6uyarcbnozgsreynqs35nbxhmm